FreeTheAI

FDA Accepts Genentech's BLA for Vamikibart in UME with July 2027 Target

BullishMedium impact
RHOCHF 361.85 −1.70%

Genentech, Inc., a member of Roche Holding Ltd (BX:RHO), announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for vamikibart in uveitic macular edema. The regulatory acceptance follows 52-week Phase III clinical data showing sustained efficacy and safety. Applications for the treatment have also been accepted by regulatory authorities in the European Union, China, and Japan.

If approved, vamikibart will represent the first non-steroid targeted therapy for patients with uveitic macular edema. Results from the 52-week study demonstrated a low need for retreatment after week 16, which could lower treatment burden for patients and support clinical adoption across global markets.

A final regulatory decision from the FDA is targeted for July 2027. Market participants will be monitoring the upcoming review timeline and future market entry steps. Shares of Roche Holding Ltd (BX:RHO) traded down 1.70% at 361.8 CHF today.

Key points

  • FDA accepted the BLA for Genentech's vamikibart to treat uveitic macular edema, with a decision expected by July 2027.
  • Phase III trial results showed sustained efficacy and safety over 52 weeks with low retreatment needs after week 16.
  • Vamikibart is positioned to become the first non-steroid targeted therapy for uveitic macular edema.
  • Regulatory submissions have also been accepted for review in the European Union, China, and Japan.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is vamikibart and what condition does it treat?

Vamikibart is a targeted, non-steroid therapy evaluated for the treatment of uveitic macular edema.

When will the FDA decide on vamikibart's approval?

The FDA is expected to make a regulatory decision on the application by July 2027.

Has vamikibart been submitted for approval outside the United States?

Yes, regulatory filings for vamikibart have also been accepted in the European Union, China, and Japan.